Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPVAUT)

• Drug Name: CCX872 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic tumour	2C10	Phase 2	[1]
Diabetic nephropathy	GB61.Z	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMPVAUT

Molecule-Related Drug Atlas

Drug(s) Targeting C-C chemokine receptor type 2 (CCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cenicriviroc	DM4V8WF	Human immunodeficiency virus infection	1C62	Phase 2	[4]
MLN1202	DM24SOL	Metastatic cancer	2D50-2E2Z	Phase 2	[5]
BMS-813160	DMKY638	Diabetic nephropathy	GB61.Z	Phase 2	[6]
CCX-140	DMJ9XCO	Diabetic nephropathy	GB61.Z	Phase 2	[7]
AZD-2423	DMF34UY	Chronic obstructive pulmonary disease	CA22	Phase 2	[8]
MK-0812	DMRT8K4	Multiple sclerosis	8A40	Phase 2	[9]
Aminoguanidine	DMJQDUC	Diabetic retinopathy	9B71.0	Phase 1	[10]
TAK-202	DMVYEFZ	Melanoma	2C30	Phase 1	[1]
OPL-CCL2-LPM	DM3HOUX	Arthritis	FA20	Phase 1	[11]
CNTX-6970	DMCOJM7	Inflammatory pain	MG30.42	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 2 (CCR2)	TTFZYTO	CCR2_HUMAN	Inhibitor	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02345408) Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
• [3] Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis. The Lancet Volume 383, Supplement 1, 26 February 2014, Pages S78.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [6] A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
• [7] Present and future in the treatment of diabetic kidney disease. J Diabetes Res. 2015;2015:801348.
• [8] CA patent application no. 841416, Method of selecting therapeutic indications.
• [9] Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods. 2010 Jan 31;352(1-2):101-10.
• [10] Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients. Incyte Corporation. 2005.
• [11] Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol. 2009 February; 155(2): 295-303.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)